Are Lispro and Novolog the Same Type of Insulin?

Lispro (sold as Humalog) and Novolog (insulin aspart) are not the same insulin, but they belong to the same class: rapid-acting insulin analogs designed to cover meals. Both were engineered from human insulin using recombinant DNA technology, and both work faster than older regular insulin. Head-to-head trials consistently show they produce nearly identical blood-sugar control, and in clinical practice most people can use either one interchangeably under a doctor’s guidance. The differences that do exist are molecular and sometimes practical, and they become relevant in specific situations like pump use, insurance formulary switches, and the newer ultra-rapid formulations each product has spawned.

How They Were Built and Why the Molecules Differ

Both lispro and aspart were created by tweaking the amino acid sequence of human insulin so that the molecule breaks apart faster after injection. Human insulin naturally clumps into clusters of six molecules called hexamers in solution. Those hexamers have to separate into single molecules before insulin can enter the bloodstream, which is why regular insulin takes a while to kick in. The first rapid-acting analog to reach the market was lispro, approved by the FDA in 1996. Its designers swapped the positions of two amino acids near the end of the insulin molecule’s B-chain, which made the hexamers fall apart more quickly once injected under the skin.¹ Aspart, approved a few years later, took a different approach: it replaced a single amino acid at one position on the B-chain with aspartic acid, achieving the same result of faster hexamer dissociation through a slightly different structural trick.

In both formulations, zinc and small preservative molecules called phenolic compounds are added to hold the insulin in stable hexamer form while it sits in the vial or pen. Once injected, those stabilizing agents dilute into surrounding tissue, and the hexamers begin breaking apart. Laboratory studies show that this dissociation happens over a range of seconds to about an hour depending on the concentration of those phenolic additives, and the speed is broadly similar for both lispro and aspart formulations.² So the two molecules reach the bloodstream at roughly the same pace, even though they got there through different amino acid modifications.

Do They Control Blood Sugar Equally Well?

The short answer from the clinical trial literature is yes. A systematic review of randomized controlled trials comparing lispro and aspart found no meaningful difference in their ability to lower blood sugar or in their safety profiles across people with diabetes.³ Individual studies back this up. In a trial of people newly diagnosed with type 2 diabetes who were monitored with continuous glucose monitors, HbA1c dropped by about 8.1% in the aspart group and about 8.5% in the lispro group from baseline, with no statistically significant difference between the two.⁴

This pattern holds across different age groups too. A randomized trial in children and adolescents with type 1 diabetes using insulin pumps found that aspart was noninferior to lispro, with no significant differences in fasting glucose, hyperglycemia rates, or hypoglycemic episodes after 16 weeks.⁵ For practical purposes, if you are choosing between the two purely based on how well they cover meals, the evidence says you can expect the same results from either one.

Does Injection Timing Matter More Than Which One You Use?

Far more than most people realize. Both lispro and aspart are often injected right at mealtime or even after a few bites, but research suggests that injecting either one about 15 to 20 minutes before eating produces substantially better results. A review of the literature found that pre-meal dosing led to roughly 30% lower post-meal glucose levels compared to dosing at the start of the meal, along with less post-meal hypoglycemia when blood sugar was in range beforehand.⁶ Meanwhile, injecting after a meal was less effective at controlling the glucose spike and carried a higher risk of hypoglycemia later.

A more recent study in hospitalized patients painted an even starker picture. When the insulin bolus was given before the meal, the four-hour post-meal time spent in a healthy glucose range was about 48%. When the bolus was delayed until more than five minutes after the meal started (with an average delay of nearly an hour), that number dropped to just 24%.⁷ The takeaway is that getting the timing right with whichever rapid-acting insulin you use matters more than which rapid-acting insulin you pick.

Behavior in Insulin Pumps

Both lispro and aspart are widely used in insulin pumps, and for the most part they perform similarly. A systematic review of stability and performance in pump systems found that the overall stability of lispro, aspart, and a third rapid-acting analog (glulisine) was comparable, though glulisine was more prone to clumping and catheter blockages.⁸ In a laboratory test simulating five days of continuous infusion at low flow rates, aspart had an overall catheter occlusion probability of about 9%, while lispro came in at roughly 16%. Glulisine was considerably worse at around 41%.⁹

That difference in occlusion rates between aspart and lispro sounds significant in percentage terms, but clinical trials have not translated it into a meaningful difference in outcomes. The pediatric pump trial mentioned earlier found equivalent glucose control and safety with either insulin over 16 weeks of real-world pump use.⁵ If you are on a pump and being asked to switch from one to the other, the clinical evidence suggests it should be a smooth transition, though it is worth keeping an eye on infusion site issues and checking with your care team about any needed dose adjustments.

Ultra-Rapid Formulations and How They Change the Picture

Both lispro and aspart now have “ultra-rapid” successors that add excipients to push insulin into the bloodstream even faster. For aspart, that product is Fiasp (faster-acting insulin aspart), which adds niacinamide and an amino acid to speed absorption. For lispro, it is Lyumjev (ultra-rapid lispro, or URLi), which uses citrate and treprostinil to increase local blood flow at the injection site. These are not new insulin molecules but reformulations of the originals with absorption-enhancing additives.

A head-to-head trial comparing BioChaperone Lispro (a next-generation ultra-rapid lispro formulation) with Fiasp and standard aspart in insulin pumps found that the ultra-rapid lispro version had a significantly faster onset and offset compared with standard aspart, and a similar early action profile to Fiasp with a faster tail-off.¹⁰ A systematic review and meta-analysis has also examined how ultra-rapid insulins perform in automated insulin delivery (closed-loop) systems, comparing them against their rapid-acting parent molecules.¹¹ The general finding is that ultra-rapid versions can shave down post-meal spikes a bit more, but the overall difference in long-term glucose control (as measured by HbA1c) is modest.

In the pediatric setting, a large phase 3 trial (PRONTO-Peds) found that ultra-rapid lispro achieved similar overall HbA1c reduction compared with standard lispro in children and adolescents with type 1 diabetes, but produced significantly lower blood sugar readings one hour after breakfast and dinner. The tradeoff was a slightly higher rate of low blood sugar in the two hours right after dosing, and more injection-site reactions with the ultra-rapid version (around 8% versus about 3% with standard lispro), though all reactions were mild or moderate.¹²

One area where you might expect ultra-rapid insulin to shine is exercise. A randomized trial comparing ultra-rapid aspart with standard aspart around moderate-intensity exercise found that the choice between the two mattered less than how much the dose was reduced before exercising. Cutting the mealtime dose by 50% versus 75% had a bigger effect on blood sugar during activity than swapping between the two formulations.¹³ In other words, dose adjustments still dwarf formulation differences.

Mixing Lispro with Longer-Acting Insulin in the Same Syringe

Some people on a basal-bolus regimen prefer to draw up both their rapid-acting and their intermediate-acting insulin (NPH) into the same syringe to reduce injections. This works with lispro: a study showed that when lispro was mixed with NPH in the same syringe, its rapid action profile was preserved. Peak insulin levels, total glucose disposal, and peak glucose infusion rates were not significantly different from injecting lispro alone, and the time to peak insulin concentration stayed fast in both unmixed and just-mixed conditions.¹⁴ Aspart can also be mixed with NPH, though the general guidance is the same for both: draw up the rapid-acting insulin first, inject promptly after mixing, and do not store the mixture. This mixing question is somewhat dated given the widespread shift to long-acting analogs like glargine and degludec (which cannot be mixed with rapid-acting insulins), but for people still using NPH, it is a reassuring data point.

Insurance Switches and Why They Go Wrong

For many people, the decision between lispro and aspart is not clinical but financial. Insurance formularies frequently prefer one over the other, and a plan can change its preferred product from year to year. In theory, since the two perform equivalently, switching should be seamless. In practice, it sometimes is not. A case report documented what happened when a health plan simultaneously switched many subscribers to a different rapid-acting insulin. The mass switch triggered a drug shortage in the local area, and one patient could not fill her new prescription in time. She was hospitalized for three days with diabetic ketoacidosis, a dangerous complication of uncontrolled blood sugar.¹⁵

This kind of “non-medical switching,” where the change is driven by cost savings rather than clinical need, is a growing concern in diabetes care. The pharmacological equivalence of lispro and aspart makes insurance companies comfortable mandating swaps, but the logistics of actually getting the new insulin into a patient’s hands sometimes fall apart. The lesson is not that switching is inherently dangerous, but that any switch requires coordination: a new prescription needs to be written, the pharmacy needs to have the product in stock, and the patient needs to understand that while the insulin behaves nearly identically, pen devices and cartridges are not cross-compatible. If your insurer requests a switch, give yourself a buffer of extra supply before the changeover.

The Biosimilar Landscape

Adding another layer of complexity, both lispro and aspart now have biosimilar versions. A biosimilar is a near-copy of a biologic drug that has been shown to match the original in safety and efficacy. The regulatory path for biosimilar insulins in the United States was formalized under the Biologics Price Competition and Innovations Act, which introduced an abbreviated approval process and the option for a biosimilar to apply for interchangeability status with its reference product.¹⁶ An interchangeable biosimilar can be substituted at the pharmacy without calling the prescriber, much like a generic version of a traditional drug.

Several biosimilar and follow-on versions of both lispro and aspart are now available, often at lower list prices. The practical implication is that when you see a prescription for “insulin lispro” or “insulin aspart,” the specific product you receive may come from the original manufacturer or from a biosimilar maker. These biosimilars have gone through rigorous testing to demonstrate they produce the same clinical outcome as the reference product. For patients, the biggest advantage is cost savings, but it also means one more variable to track on your pharmacy receipts.

Rapid-Acting Insulin in Pregnancy

For pregnant women with preexisting diabetes, choosing a mealtime insulin involves weighing a slightly different set of concerns. A study comparing insulin lispro (as the rapid-acting analog) with regular human insulin in women with pregestational diabetes found no significant difference in congenital malformation rates between the two groups. Women on the rapid-acting analog needed smaller insulin doses throughout pregnancy. Severe hypoglycemia was significantly less common in the analog group, occurring in about 2% of those women compared with 10% on human insulin. The one wrinkle: neonatal hypoglycemia was more frequent in the rapid-acting analog group, though the authors attributed this to the concurrent use of an insulin pump rather than to the insulin molecule itself.¹⁷

Both lispro and aspart have accumulated safety data in pregnancy, and current guidelines generally consider both acceptable for use. The choice between them in pregnancy, as in most other contexts, tends to come down to which one a woman was already using before conceiving and what her insurance covers. Switching insulins during pregnancy is generally avoided unless there is a compelling reason, because any transition carries a short-term risk of under- or over-dosing while the patient adjusts.

Formulation Stability Outside the Fridge

One practical question people rarely think to ask until they are traveling or dealing with a hot climate: do lispro and aspart hold up equally well outside refrigeration? Both are officially rated for 28 days of room-temperature storage once opened, but the details of what keeps each one stable differ. The excipients in each formulation, including zinc, phenolic preservatives, and buffering agents, are tuned to the specific insulin molecule they contain. Research into formulation stability has shown that adding certain polymer excipients to lispro can dramatically extend its stability at stressed temperatures, with some experimental formulations lasting several times longer than commercial Humalog before aggregating.¹⁸ These are research findings, not commercially available products yet, but they hint at a future where rapid-acting insulins could survive much longer in imperfect storage conditions.

For now, both products should be treated the same way: refrigerate unopened vials and pens, and once in use, keep them below about 86°F (30°C). Neither is meaningfully more fragile than the other in real-world handling. If your insulin has turned cloudy, developed particles, or been exposed to extreme heat or freezing, discard it regardless of brand. The visual check is the same for both.

Why the “Same but Different” Answer Keeps Coming Up

The recombinant DNA era gave us the ability to design insulin analogs with specific absorption profiles, and the first generation of rapid-acting analogs, lispro and aspart, ended up converging on almost identical clinical performance despite taking different molecular routes to get there.¹⁹ This makes them genuinely interchangeable for most clinical purposes, but it does not make them identical products. They are made by different companies, packaged in different devices, covered differently by insurance plans, and formulated with different excipient profiles that can matter in niche situations like pump occlusion rates or experimental stability extensions. For the person newly prescribed a rapid-acting insulin, the reassuring reality is that either one will do the job. For the person being forced to switch by an insurer, the reassuring evidence is that the switch is medically safe, even if the logistics require attention. And for anyone eyeing the ultra-rapid versions, the upgrade is real but incremental, delivering slightly sharper post-meal control rather than a fundamentally different experience of managing diabetes.